MedPath

Velicept Therapeutics, Inc.

Velicept Therapeutics, Inc. logo
🇺🇸United States
Ownership
Private
Established
2015-01-01
Employees
1K
Market Cap
-
Website
http://www.velicept.com

Clinical Trials

3

Active:0
Completed:3

Trial Phases

2 Phases

Phase 1:1
Phase 2:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials

Phase 2
2 (66.7%)
Phase 1
1 (33.3%)

A Study to Evaluate Once Daily Low Dose and High Dose Solabegron or Placebo Given for 12 Weeks to Treat Women With Symptoms of Overactive Bladder: Sudden Urge to Urinate, Frequent Urination Associated With Wetting Episodes (VEL-2001)

Phase 2
Completed
Conditions
Overactive Bladder
Interventions
First Posted Date
2018-07-20
Last Posted Date
2020-03-02
Lead Sponsor
Velicept Therapeutics, Inc.
Target Recruit Count
1413
Registration Number
NCT03594058
Locations
🇺🇸

Velicept Investigative Site - Birmingham, Birmingham, Alabama, United States

🇺🇸

Velicept Investigative Site - Guntersville, Guntersville, Alabama, United States

🇺🇸

Velicept Investigative Site - Saraland, Saraland, Alabama, United States

and more 62 locations

Evaluation of the Efficacy and Safety of Solabegron Tablets for Treatment of Overactive Bladder in Adult Women

Phase 2
Completed
Conditions
Overactive Bladder
Interventions
First Posted Date
2018-03-23
Last Posted Date
2020-03-02
Lead Sponsor
Velicept Therapeutics, Inc.
Target Recruit Count
438
Registration Number
NCT03475706
Locations
🇺🇸

Velicept Investigative Site - Birmingham, Birmingham, Alabama, United States

🇺🇸

Velicept Investigative Site - Gulf Shores, Gulf Shores, Alabama, United States

🇺🇸

Velicept Investigative Site - Mobile, Mobile, Alabama, United States

and more 77 locations

Evaluate the Safety, Tolerability and PK of Different Formulations of Orally Administered Solabegron in Healthy Male Subjects

Phase 1
Completed
Conditions
Healthy Subjects, Overactive Bladder
Interventions
First Posted Date
2016-10-19
Last Posted Date
2019-04-24
Lead Sponsor
Velicept Therapeutics, Inc.
Target Recruit Count
24
Registration Number
NCT02938507

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.